Skip to content
Uveitis

Cryptococcal Chorioretinitis

Cryptococcal choroiditis is an infectious choroiditis caused by the encapsulated yeast-like fungus Cryptococcus neoformans¹˒². It is one of the AIDS-defining illnesses and an important cause of infectious choroiditis in immunocompromised patients³.

Choroidal lesions may appear as an initial ocular manifestation of disseminated cryptococcosis or meningitis. Without treatment, the disease can become fatal within weeks, making early detection and treatment extremely important.

Pathogen and Infection Route

Pathogen: Cryptococcus neoformans (encapsulated yeast-like fungus)

Source of infection: Most commonly found in dried pigeon droppings

Route of infection: Inhalation of aerosolized spores leads to pulmonary infection → hematogenous dissemination

Epidemiology: 957,900 cases of cryptococcal meningoencephalitis annually, with over 600,000 deaths (2008 survey)

Major Risk Factors

HIV/AIDS: CD4 < 100 cells/µL is the greatest risk

Other immunodeficiencies: Organ transplantation, malignancy, immunosuppressant use, long-term corticosteroid use

Environmental exposure: Pigeon droppings, decaying wood, tree hollows, contaminated soil

Prevention: Promptly administer prophylactic antifungal drugs once CD4 < 100 cells/µL is identified

Cryptococcal chorioretinitis presents with nonspecific symptoms in the early stage.

  • Mild headache, fatigue, fever (systemic symptoms)
  • Intermittent blurred vision, decreased visual acuity
  • Symptoms may fluctuate between exacerbation and remission

In severely immunocompromised states, the inflammatory response itself is poor, and there is a risk of progression with minimal symptoms.

Fundus findings:

Cryptococcal chorioretinitis typically presents with the following findings.

  • Creamy yellow choroidal lesions: Fungal colonies in the choroid³
  • White-centered hemorrhages: Roth spot-like hemorrhages³˒⁶

In severe immunodeficiency, inflammatory reactions such as vitritis are often minimal. This is because the immune function required to mount an intraocular immune response is markedly reduced.

Imaging findings:

TestFindings
Fluorescein angiography (FA)Early: blockage of choroidal filling (hypofluorescence). Late: lesions with reduced filling
Indocyanine green angiography (ICG)Used to evaluate choroidal lesions
OCTChoroidal thickening, hyperreflective choroidal lesions. Retinal pigment epithelium (RPE) destruction is not typical

Note that these imaging findings are nonspecific.

Q Why is vitritis less common in cryptococcal choroiditis?
A

In severe immunodeficiency, the immune function itself is significantly impaired, making it difficult to recruit inflammatory cells into the vitreous. Since CD4-positive T cells are reduced to 100 cells/µL or less, inflammatory responses to infection are less likely to occur. Therefore, vitritis and anterior chamber inflammation, which are typically seen in infectious endophthalmitis, are often mild.

C. neoformans is an encapsulated yeast-like fungus widely present in the environment. It is particularly abundant in dried pigeon droppings, and inhalation of aerosolized spores is the main route of infection.

Major risk factors:

  • HIV infection/AIDS (CD4+ cell count < 100 cells/µL)
  • Immunosuppressive therapy after solid organ transplantation
  • Hematologic malignancies (e.g., lymphoma)
  • Long-term corticosteroid use
  • Other immunosuppressive conditions (e.g., treatment for autoimmune diseases)

Environmental risks:

  • Exposure to pigeon droppings
  • Decayed wood or tree hollows
  • Contaminated soil
  • Unwashed raw fruits

Since cryptococcal chorioretinitis is an ocular manifestation of systemic disease, systemic evaluation is essential.

Initial Evaluation Process:

  1. Detailed medical history (confirmation of immunosuppressive status and exposure history)
  2. Neurological examination (assessment of increased intracranial pressure and cranial nerve symptoms)
  3. Serum cryptococcal antigen (CrAg) test
  4. If CrAg positive or symptoms present, perform lumbar puncture (LP)
  5. Cerebrospinal fluid (CSF) culture, CrAg test, India ink staining

Accuracy of diagnostic tests:

TestCharacteristics
LFA method (CrAg lateral flow assay)Sensitivity and specificity both >98%. Recommended diagnostic method.
CSF fungal cultureUsed for definitive diagnosis. Sensitivity decreases with early or prior antifungal therapy.
Mucicarmine stainIdentifies the thick capsule of C. neoformans.
India Ink StainIdentifies thick capsule. Useful for rapid diagnosis

Differential Diagnosis:

Differential diagnosis of cryptococcal chorioretinitis in advanced AIDS patients:

  • Toxoplasmosis (necrotic lesion at the posterior pole of the fundus)
  • Pneumocystis jiroveci infection (confirmed by induced sputum/BAL)
  • Mycobacterium tuberculosis (evaluated by chest X-ray)
  • Histoplasma capsulatum (confirmed by histopathological examination)
  • Candida albicans (common in catheter-related infections)
Q Can cryptococcal chorioretinitis be diagnosed based on fundus findings alone?
A

Fundus findings (milky-white to yellow choroidal lesions + hemorrhage with central white spots) are characteristic, but definitive diagnosis requires serum and cerebrospinal fluid CrAg testing and culture. FA, ICG, and OCT findings are all non-specific, and differentiation from other infectious chorioretinitis may be difficult based on ocular findings alone. It is important to comprehensively evaluate the systemic condition (degree of immunodeficiency, risk of other infections).

The global guidelines of the European Confederation of Medical Mycology (ECMM) and the International Society for Human and Animal Mycology (ISHAM) (Chang et al., 2024)¹, as well as the clinical practice guidelines of the Infectious Diseases Society of America (IDSA) (Perfect et al., 2010)², recommend that all disseminated cryptococcosis outside the central nervous system and lungs, including ocular lesions, be treated in the same manner as central nervous system disease.

Three-Step Treatment Regimen:

StepRegimenDuration
Induction therapyLiposomal amphotericin B 3–4 mg/kg/day + flucytosine 25 mg/kg 4 times daily2 weeks
Consolidation therapyFluconazole 400–800 mg once daily8 weeks
Maintenance therapyFluconazole 200 mg once daily12–18 months

Alternative therapy in resource-limited settings (induction phase):

Single high-dose liposomal amphotericin B (10 mg/kg) + flucytosine 100 mg/kg/day + fluconazole 1200 mg/day for 2 weeks.

  • Close follow-up is needed in the early stages until clinical response is observed
  • Immunosuppressive therapy should be discontinued for at least 2 weeks after starting antifungal therapy
  • Since recurrence is not uncommon, medical treatment should be tapered slowly

In some cases, the condition may rapidly progress to endophthalmitis, requiring the following surgical treatments:

Q If treatment is successful, can cryptococcal chorioretinitis be cured?
A

With appropriate treatment, acute infection can be controlled, but long-term maintenance therapy (fluconazole for 12–18 months) is required. Due to high risk of recurrence, maintenance therapy must be tapered carefully. Management of underlying immunodeficiency (especially HIV) is also essential, and recovery of CD4 count significantly affects long-term prognosis. Visual prognosis depends on the extent of lesions at the time of detection and the speed of treatment initiation.

C. neoformans is a yeast-like fungus with a polysaccharide capsule. The capsule functions as an immune evasion mechanism by suppressing complement activation and avoiding phagocytosis by macrophages.

Progression of infection:

  1. Inhalation of spores → initial infection in the lungs
  2. In immunocompromised hosts, pulmonary infection progresses and persists.
  3. Hematogenous dissemination to the whole body, including the choroidal vasculature.
  4. Colonization of the choroid → local fungal proliferation → formation of choroiditis.

Why intraocular inflammation is scarce in severe immunodeficiency

Section titled “Why intraocular inflammation is scarce in severe immunodeficiency”

Under normal immune conditions, Th1-type cellular immunity is activated against infection, causing inflammation. However, when CD4-positive T cells are severely depleted, this inflammatory response is not triggered. Therefore, in cryptococcal choroiditis, inflammatory signs such as vitritis are scarce, and the disease progresses with mild symptoms.

The abundant blood flow and vascular structure (fenestrated capillaries) of the choroid facilitate the colonization of hematogenously disseminated C. neoformans. Proliferation of fungal colonies leads to the formation of milky-white to yellow choroidal lesions. Spread to adjacent retinal capillaries may cause intraretinal hemorrhages with central white spots (resembling Roth spots).

7. Recent Research and Future Perspectives

Section titled “7. Recent Research and Future Perspectives”

Cryptococcosis continues to impose a severe disease burden, especially in low- and middle-income countries¹. Visual impairment is frequent in cryptococcal meningitis, and irreversible vision loss due to optic neuropathy or elevated intracranial pressure has been reported⁴˒⁵. Recent research trends include the following:

  • Widespread use of lateral flow assay (LFA): Simple diagnostic kits with sensitivity and specificity over 98% have enabled early diagnosis even in resource-limited healthcare settings.
  • Evaluation of single high-dose amphotericin B: As an alternative to the conventional two-week regimen, single-dose protocols are being studied to improve access in resource-limited areas.
  • Advances in HIV treatment: Widespread ART use is expected to restore CD4 counts, but management of IRIS (immune reconstitution inflammatory syndrome) remains an important challenge.
  • Drug transfer into the eye: Fluconazole has relatively high permeability through the blood-ocular barrier, providing good access to ocular lesions.
  1. Chang CC, Harrison TS, Bicanic TA, et al. Global guideline for the diagnosis and management of cryptococcosis: an initiative of the ECMM and ISHAM in cooperation with the ASM. Lancet Infect Dis. 2024;24(8):e495-e512. PMID: 38346436. doi:10.1016/S1473-3099(23)00731-4
  2. Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2010;50(3):291-322. PMID: 20047480. doi:10.1086/649858
  3. Paiva A, Biancardi AL, Curi A. Clinical-laboratory outcome of Cryptococcus sp. multifocal choroiditis in acquired immunodeficiency syndrome patients. Ocul Immunol Inflamm. 2024;32(10):2421-2427. PMID: 39250593. doi:10.1080/09273948.2024.2392201
  4. Duggan J, Walls HM. Ocular complications of cryptococcal meningitis in patients with HIV: report of two cases and review of the literature. J Int Assoc Physicians AIDS Care (JIAPAC). 2012;11(5):283-288. PMID: 22713686. doi:10.1177/1545109712448537
  5. Espino Barros Palau A, Morgan ML, Foroozan R, Lee AG. Neuro-ophthalmic presentations and treatment of cryptococcal meningitis-related increased intracranial pressure. Can J Ophthalmol. 2014;49(5):473-477. PMID: 25284106. doi:10.1016/j.jcjo.2014.06.012
  6. Joseph J, Sharma S, Narayanan R. Endogenous Cryptococcus neoformans endophthalmitis with subretinal abscess in a HIV-infected man. Indian J Ophthalmol. 2018;66(7):1015-1017. PMID: 29941759. doi:10.4103/ijo.IJO_60_18

Copy the article text and paste it into your preferred AI assistant.